1 Equity and efficiency in global respiratory virus genomic surveillance

- Simon P.J. de Jong¹, Brooke E. Nichols^{1,2,3}, Menno D. de Jong¹, Alvin X. Han^{1,*}, Colin A.
 Russell^{1,3,*}
- 4 ¹Department of Medical Microbiology & Infection Prevention, Amsterdam University
- 5 Medical Centers, University of Amsterdam, Amsterdam, The Netherlands
- 6 ²Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland
- ⁷ ³Department of Global Health, Boston University, Boston, MA, USA
- 8 *Contributed equally
- 9 Correspondence to C.A.R. c.a.russell@amsterdamumc.nl

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

10 **Summary**

11

12 Public health interventions for respiratory virus outbreaks increasingly rely on genomic 13 sequencing for the rapid identification of new (variant) viruses^{1–5}. However, global sequencing efforts are unevenly distributed^{6–9}, with some high-income countries sequencing 14 15 at >100,000 times the rate of many low-income countries. Given the importance of virus 16 genomic sequencing and substantial global disparities in sequencing capacities, there is a 17 need for meaningful minimum sequencing targets and functional upper bounds that maximise resource efficiency^{1,2,8,10,11}. Here, using mathematical models and analyses of data on global 18 SARS-CoV-2 sequencing output in 2022, we show that increases in sequencing rates typical 19 20 of low-income countries are >100-fold more effective at reducing time to detection of new 21 variants than increases from rates typical of high-income countries. We find that relative to 22 2022 sequencing rates, establishing a minimum respiratory virus sequencing capacity of two 23 sequences per million people per week (S/M/wk) with a two-week time from sample 24 collection to sequence deposition in all countries, while simultaneously capping sequencing 25 rates at 30 S/M/wk in all countries, could reduce mean time to first variant detection globally 26 by weeks-to-months while also reducing global sequencing output by >60%. Our results 27 show that investing in a minimum global respiratory virus sequencing capacity is far more 28 effective at improving variant surveillance than expanding local sequencing efforts in 29 countries with existing high-intensity respiratory virus surveillance programs and can guide 30 rightsizing of global respiratory virus genomic surveillance infrastructure.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23297901; this version posted November 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

31 Main

32

33 Genomic surveillance of respiratory viruses has expanded substantially since the late 1990s 34 and is now a critical component of public health preparedness and response, particularly for 35 identifying and monitoring the spread of new virus variants of concern^{1–5}. However, genomic surveillance infrastructure is unequally distributed globally^{2,6,8,9}. For viruses collected in 2022 36 alone, ~7 million SARS-CoV-2 genomes have been submitted to GISAID (www.gisaid.org, 37 38 the most commonly used repository for respiratory virus genome sequencing data), but 39 country-level sequencing rates as estimated from GISAID submissions varied by over six 40 orders of magnitude (Fig. 1a), with 17 countries not depositing any sequences. Half of all 41 publicly shared SARS-CoV-2 genomes from samples collected in 2022 originated from 42 countries that account for only 4.4% of the global human population, while countries 43 comprising half of the global population deposited only 0.7% of available genomes (Fig. 1b). 44 Additionally, the time from sample collection to sequence deposition (henceforth, turnaround 45 time) ranged across countries from less than two weeks to hundreds of days (interquartile 46 range 28-108 days; Fig. 1c). Sequencing rates and median turnaround times (Spearman's $\rho =$ 0.79, $P = 6.3 \times 10^{-41}$; $\rho = -0.54$, $P = 7.1 \times 10^{-16}$, respectively) are strongly correlated with per 47 *capita* GDP, indicating that the capacity of a country's genomic surveillance infrastructure 48 49 correlates with its economic output (Fig. 1d, Extended Data Fig. 1). As new variants can 50 potentially emerge in any country, this global variability in genomic surveillance capacity raises important questions about the amount of sequencing and associated turnaround time 51 needed to effectively and efficiently detect new virus variants worldwide^{1,2,8,10,12,13}. 52 53

54 To address these questions, we deterministically simulated the emergence of a variant virus in 55 the background of circulating wildtype virus with susceptible-infected-recovered (SIR) dynamics under different scenarios of variant emergence (i.e. initial R_e of wildtype and 56 variant viruses and prevalence of wildtype virus; Extended Data Fig. 2). Using the 57 simulations, we computed the expected day of variant detection with 95% confidence based 58 59 on binomial sampling for different sequencing rates. We then derived a new mathematical 60 model characterising the relationship between sequencing rates and time to detection of the new virus variant. For a variant virus, introduced in a population at an initial frequency f_0 , of 61 62 which the change in variant proportion through time can be described by a logistic growth 63 rate s, the time since variant introduction after which the variant virus is expected to have

64 been detected with confidence level 1-q, when sequencing *n* samples per unit time, is equal to $(\log[(q^{-s/n}-1)/f_0]+1)/s$. This model is applicable to all respiratory viruses that can be described 65 66 by SIR dynamics¹⁴, including SARS-CoV-2, respiratory syncytial virus, and pandemic or 67 seasonal influenza viruses.

68

69 For all modelled scenarios of variant emergence (Extended Data Fig. 2), time to variant 70 detection rapidly decreased as sequencing rate increased up to ~10 S/M/wk (Fig. 2a, 71 Extended Data Fig. 3a). In comparison, the benefits of further increases in sequencing rate 72 beyond 10 S/M/wk were much smaller (Fig 2a). In 2022, many high-income countries 73 sequenced SARS-CoV-2 genomes at rates well in excess of 10 S/M/wk (some >>100 74 S/M/wk), whereas many lower-and-middle-income countries sequenced at rates (<<1 S/M/k 75 in many countries) at which, in absolute terms, small increases in sequencing rates would 76 substantially speed up variant detection (Fig. 1a, 2b, Extended Data Fig. 3b). For example, in 77 a country of 100 million people sequencing at the median 2022 SARS-CoV-2 sequencing rate 78 in low-income countries (0.035 S/M/wk), increasing the sequencing rate by 1 S/M/wk would 79 reduce the time to detection of a variant with $R_e = 1.6$ at 95% confidence by ~28 days, given 80 a wildtype prevalence of 0.5% and a wildtype R_e of 1.1 at time of variant emergence. In 81 contrast, if the same country was sequencing at the 2022 median high-income country rate 82 (58.7 S/M/wk), the reduction in time to detection resulting from the same 1 S/M/wk increase in sequencing rate would be only 3.5 hours (Fig. 2b). 83

84

85 Sequencing rates similarly impact the number of people that will have been infected by the 86 variant when it is first detected (Fig. 2c, Extended Data Fig. 4a). In the same scenario of 87 variant emergence described above (variant $R_e = 1.6$, wildtype $R_e = 1.1$, wildtype prevalence 88 = 0.5% at variant emergence), given a sequencing turnaround time of two weeks, the 89 expected number of variant infections by the day of first detection with 95% confidence 90 amounted to ~4.7 million in a country of 100 million people sequencing at the median low-91 income country rate. Increasing the sequencing rate in this country by 1 S/M/wk would 92 reduce the expected number of variant infections by the time of detection by \sim 4.5 million 93 infections (Fig. 2d). In contrast, only ~3,400 variant infections would be expected by the day 94 of first detection in a country sequencing at the median 2022 sequencing rate in high-income 95 countries (Fig. 2c), and increasing the sequencing rate in this country by the same 1 S/M/wk 96 would only reduce the expected number of variant infections by the day of first detection by 97 ~60 infections (Fig. 2d). Hence, for reducing a variant's extent of spread through a

98 population by the time of first detection, the benefits of increases in sequencing rates are far 99 more substantial at lower sequencing rates (Fig. 2d, Extended Data Fig. 4b).

100

101 In addition to sequencing rate, turnaround time is an essential component of effective genomic surveillance^{1,7,8,15}. For reducing time to variant detection, any reduction in 102 103 turnaround time is functionally equivalent to a fold increase in sequencing rate, and the 104 magnitude of this equivalent fold increase depends on the scenario of variant emergence (Fig. 2e). For example, if the wildtype virus is circulating with $R_e = 1$ at 0.1% prevalence, reducing 105 turnaround time by three weeks is equivalent to increasing the sequencing rate 2.4-fold for 106 107 detecting a variant with $R_e = 1.2$. In contrast, for detecting a variant with $R_e = 2$, the same 108 three-week reduction in turnaround time is equivalent to a ~55-fold increase in sequencing 109 rate. As reductions in turnaround time might be more cost-efficient than increases in 110 sequencing rate, the benefits of increasing sequencing output should be carefully weighed 111 against the gains from strengthening the ancillary infrastructure necessary for rapid 112 sequencing. 113

114 For individual countries, the above results inform how resources can be efficiently allocated 115 to detect new virus variants locally. However, new (variant) viruses can emerge anywhere globally^{1,16}. The global time to variant detection is shaped by (1) the global human mobility 116 network, which determines how the virus spreads internationally^{17–22} and (2) the global 117 genomic surveillance network, which determines how rapidly it can be detected in individual 118 119 countries where it is present. To investigate how global variation in respiratory virus genomic surveillance infrastructure impacts the speed of new variant detection, we simulated global 120 121 variant spread using a global metapopulation model, validated against GLEAM^{23,24} (Extended Data Fig. 5). For each value of variant R_e , ranging from 1.2 to 2, we performed 122 123 10,000 independent simulations. In each simulation, the country where the variant emerged 124 was randomly selected based on a country population size-weighted probability. We then estimated the expected global time to variant detection for each simulation given empirical 125 126 country-specific SARS-CoV-2 sequencing rates and turnaround times in 2022 as estimated 127 from submissions to GISAID²⁵.

128

129 The mean time to first variant detection globally, averaged across all simulated variant R_e

values, was 82.1 days (95% CI 17 - 193) with substantial variability at lower values of 130

variant R_e (Fig. 3a). The global number of variant infections by the day of first global 131

detection varied widely (mean 566,413 infections, 95% CI 73 - 4,999,369) and spanned up to 132 133 five orders of magnitude for all values of variant R_e (Fig. 3b). The continent in which the 134 variant emerged strongly shaped the time to variant detection (Fig. 3c) and the number of 135 global variant infections by the day of first detection (Fig. 3d), the latter ranging from a mean 136 of 20,264 infections (95% CI 26 - 235,022) when emerging in Europe to 1,559,748 infections (95% CI 950 – 12,213,845) in case of emergence in Africa (Fig. 3d). The differences in time 137 138 to detection (Fig. 3e) and the number of variant infections by the day of detection (Fig. 3f) 139 were strongly associated with the sequencing rate in the variant's country of emergence. In 140 29.1% of all simulations, new variants were first detected outside of their continent of origin, driven especially by variants emerging in Africa (detected outside origin continent in 74.4% 141 142 of simulations), Asia (23.8%) and South America (20.0%), meaning that the variant would 143 have frequently spread widely within and between continents prior to initial detection (Fig. 144 3g, 3h).

145

146 Since reductions in time to detection resulting from increases in sequencing rate beyond ~10

147 S/M/wk (Fig. 2b) are limited, we hypothesised that reducing sequencing output in countries

148 that strongly exceeded this rate would have little effect on speed of variant detection while

149 substantially reducing global sequencing output. We re-simulated the genomic surveillance

150 process using the same metapopulation epidemic simulations and found that relative to the

151 2022 baseline (henceforth, strategy 1), the expected time to variant detection (Fig. 4a,

152 Extended Data Fig. 6a) and the expected number of variant infections by the day of detection

153 (Fig. 4b, Extended Data Fig. 6b) remained largely unchanged if sequencing rates were capped

154 at 30 S/M/wk in all countries (henceforth, strategy 2): mean time to variant detection would

155 increase by only 4.5 days, from mean 82.1 days to 86.6 days (95% CI 24-199) (Fig. 4a),

156 while global sequencing output would be reduced by 67.0% (Fig. 4c).

157

158 Because the largest reductions in time to detection are attained at relatively low sequencing

159 rates (Fig. 2b), we further hypothesised that establishing basic sequencing infrastructure

160 globally, even at a limited sequencing rate but with a low turnaround time, could substantially

161 reduce the global time to variant detection relative to the 2022 baseline. Ensuring a global

162 minimum sequencing capacity of 2 S/M/wk with a turnaround time of 14 days, while

163 maintaining sequencing output in countries that already satisfied this capacity in 2022

164 (henceforth, strategy 3), reduced mean time to global variant detection by 26.1 days to 56.0

days (95% CI 16 - 118) (Fig. 4a). The mean number of global variant infections by the day of 165

166 detection decreased from 566,413 infections (95% CI 73 – 4,999,369) to 26,415 infections

167 (95% CI 61 –196,092) (Fig. 4b). A sequencing rate of 2 S/M/wk corresponds to 0.18% of the

168 maximum country-specific SARS-CoV-2 sequencing rate in 2022 and its establishment

169 globally would increase global sequencing output by 6.0% relative to the 2022 baseline (Fig.

170 4c).

171

172 Combining the insights above, we hypothesised that reducing the inequity in the global 173 genomic surveillance could strongly improve its efficiency and effectiveness. In our 174 simulations, combining strategies 2 and 3 (i.e. capping individual countries' sequencing 175 output at 30 S/M/wk while also ensuring the minimum global capacity of 2 S/M/wk with 176 turnaround time of 14 days; henceforth, strategy 4) reduced mean time to detection and the 177 mean number of variant infections by the day of first detection to 57.7 days (95% CI 20 -178 120) and 27,717 infections (95% CI 90 – 201,028) respectively (Fig. 4a, 4b, Extended Data Fig. 6). The performance of strategy 4 is effectively identical to that of strategy 3, which 179 180 establishes the global minimum capacity but without capping individual countries' output, 181 but strategy 4 still reduces global sequencing output by 61.0% relative to the 2022 baseline 182 (Fig. 4c). While the initial costs of establishing the infrastructure necessary to achieve the 183 minimum respiratory virus sequencing capacity globally are likely to be high, our results 184 show that opportunities exist for redistribution of existing resources or investments in new 185 ones in order to achieve a more equal distribution of sequencing infrastructure across the 186 globe, yielding a global surveillance system that is more effective while more than halving 187 overall global sequencing output.

188

189 The establishment of global minimum respiratory virus sequencing capacity would also 190 increase the probability that a variant is first detected in the continent where it emerged from 191 70.9% (strategy 1) to 98.4% (strategy 4) (Fig. 4d). Consequently, in all countries, including 192 those that were to reduce their national sequencing output, the lead time between the variant's 193 first global detection and its first local case would increase (Fig. 4e). This would allow for 194 more time for potential local public health measures in preparation for variant outbreaks in all 195 countries. These benefits are particularly valuable for countries that are extensively connected 196 in the global mobility network, located largely in Europe, Asia and North America, as these 197 countries tend to experience especially early invasion and hence typically have a shorter lead 198 time a priori (Fig. 4e). Importantly, the relative performance of the different strategies for the 199 global distribution of genomic surveillance infrastructure is robust to biases in the estimates

of turnaround time resulting from delays in sequence deposition in GISAID^{26,27} (Extended 200 201 Data Fig. 7) and deviations from the assumed global mobility rates (Extended Data Fig. 8). 202

203 This study primarily focuses on the simple detection of a variant virus, but ascertaining the 204 public health risk posed by a variant requires information such as its virulence and transmissibility²⁸, that at best can only partially be inferred from genomic sequencing^{1,29-32}. 205 206 Accruing such information and translating it to public health policy likely occurs on 207 timescales beyond the reductions in time to variant detection that increases in sequencing rate 208 beyond the order of 10-30 S/M/wk can yield, thus limiting the public health impact of further 209 increases. For example, the SARS-CoV-2 Alpha variant was first detected in the UK in a 210 sample collected on 20 September 2020, likely within days of its initial emergence³³. At the 211 time, the sequencing rate in the UK was ~100 S/M/wk. However, it was not until December 212 2020 that epidemiological evidence of the variant's transmission advantage relative to preexisting viruses began to accumulate^{5,33}. Hence, sequencing at rates much lower than ~100 213 214 S/M/wk would likely have had similar public health impact. Because of the importance of 215 complementary clinical and epidemiological data, the value of investments in global genomic 216 surveillance capacity can be enhanced through clinical and public health infrastructure

development^{27,34}. 217

218

219 Our results are broadly applicable to respiratory viruses in both endemic and epidemic 220 scenarios, including potential future pandemics similar to the 2009 influenza A/H1N1pdm09 221 and COVID-19 pandemics. The global heterogeneity in genomic surveillance of SARS-CoV-2 is also apparent for other respiratory viruses, including those with extensive global public 222 223 health surveillance histories: seasonal influenza virus genomic sequencing output in the pre-224 pandemic era was similarly unequally distributed (Extended Data Fig. 9).

225

226 Our results are limited by the assumption of representative sampling in the genomic 227 surveillance process, including the ready availability and access to diagnostic tools, which does not always hold in reality 35,36. As the departure from this assumption is especially strong 228 229 in resource-constrained settings^{15,35}, the reported reductions in time to variant detection 230 resulting from the establishment of a global minimum sequencing capacity are likely 231 underestimates. Our results primarily apply to variant detection (and monitoring variant prevalence, see Extended Data Fig. 10, Supplementary Text), and not to other analyses such 232 as reconstructing geographical spread¹⁹ or targeted outbreak investigations³⁷, for which the 233

234 shape of the relationship between sequencing rate, turnaround time, and performance is likely different¹². However, initial detection is the necessary starting point for all analyses that make 235 236 use of genomic data. The proposed global minimum respiratory virus sequencing capacity 237 offers increased and faster information for public health actions targeting the identification 238 and monitoring of new variants, as well as tracking viruses through space and time 38,39 . 239 Additionally, the optimal sequencing rate depends on the characteristics of the pathogen and 240 the required timeliness of sequencing data for public health action, but a minimum capacity of 2 S/M/wk at 14 days turnaround time will even allow for relatively rapid detection when a 241 242 highly transmissibly variant emerges in a background of high wildtype incidence. The 243 balance of sequencing rate and turnaround time in our proposed minimum capacity serves as 244 a potential target, but the most resource-efficient balance of sequencing rate and turnaround 245 time could differ among countries. See Supplementary Text for further discussion of other 246 approaches and comparisons to other guidance. 247

248 Our analyses use empirical SARS-CoV-2 sequencing rates based on submissions to GISAID 249 from 2022, when COVID-19 was still a public health emergency of international concern. Although sequencing outputs have since declined in many countries^{1,2}, the fundamental 250 251 notion persists that relatively small increases in global sequencing output in the right places 252 can profoundly improve global respiratory virus genomic surveillance in ways that even large 253 increases in places with established surveillance infrastructure cannot. Establishing the necessary infrastructure for robust global genomic surveillance will require substantial 254 255 investments in countries that often have other competing public health priorities^{2,40}. Our 256 results suggest that, because the establishment of such infrastructure benefits the world at 257 large, filling this investment gap will provide a strong return on investment for well-258 resourced countries that already possess strong genomic surveillance infrastructure locally. For these countries, such investments likely represent a more efficient use of public health 259 260 resources than investments in increasing local sequencing output and should be a public 261 health priority in the post-pandemic period.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23297901; this version posted November 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



262

263 Fig. 1. The global landscape of SARS-CoV-2 genomic surveillance infrastructure in

264 **2022.** a) The distribution of non-zero weekly sequencing rates per million people, for

265 individual countries (n = 198), coloured by continent (AF: Africa, EU: Europe, OC: Oceania,

AS: Asia, NA: North America, SA: South America). **b**) The cumulative proportion of the

267 global population that accounts for a cumulative proportion of global sequence output. Solid

268 grey lines show the smallest proportion of the population that accounts for 50% of

269 sequencing output. Dashed grey lines show the smallest proportion of sequencing output that

is accounted for by 50% of the global population. c) The distribution of median country-

271 specific turnaround times (n = 198), coloured by continent. **d**) Correlation between per capita

GDP and weekly sequencing rate per million people by country (n = 188) (each circle

- 273 represents one country, coloured by continent).
- 274

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23297901; this version posted November 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .





277 Fig. 2. The dependence of time to variant detection on sequencing rate and turnaround 278 time for a single country. In all panels, lines are coloured by values of variant $R_{\rm e}$, with a 279 distinct scenario of variant emergence for each value of variant R_e ; sequencing turnaround time was assumed to be 14 days. a) Relationship between sequencing rate and the number of 280 281 days until the variant will have been detected with 95% confidence. The small black tick 282 marks on the x-axes in this plot and in **b-d** show country-specific SARS-CoV-2 sequencing rates for 2022. Vertical dotted lines correspond to the median SARS-CoV-2 sequencing rates 283 284 for high-income (HIC) and low-income (LIC) countries in 2022. b) Relationship between 285 sequencing rate and the reduction in time to variant detection that results from increasing the existing sequencing rate (x-axis) by 1 S/M/wk. c) Relationship between sequencing rate and 286 the number of variant infections by the day the variant will have been detected with 95% 287 288 confidence. d) Relationship between sequencing rate and the reduction in the number of 289 variant infections by the day of detection that results from increasing the existing sequencing 290 rate (x-axis) by 1 S/M/wk. e) Relationship between a reduction in turnaround time (in days) 291 and the fold increase in sequencing rate that would be required to effect the same reduction in time to detection if turnaround time was kept constant. 292 293





296 Fig. 3. The global time to variant detection based on the SARS-CoV-2 genomic

297 sequencing landscape in 2022. a) The distribution of days to variant detection for different 298 values of variant R_e , each with a distinct scenario of variant emergence (n = 10,000 for each

299 variant R_e). Vertical lines correspond to the median and 95% CI. b) The distribution of the

300 number of global variant infections by the day of variant detection. c) The time to variant

301 detection by variant origin continent. Thin and thick lines correspond to 95% and 50% CIs,

respectively. d) The number of global variant infections by the day of detection by variant 302

origin continent, analogous to c. e) The relationship between a country's sequencing rate and 303

304 the mean time to first global detection of a variant emerging in that country. f) The

relationship between a country's sequencing rate and the mean number of global variant 305

306 infections by the day of detection of a variant emerging in that country. g) The probability

307 that the variant is first detected in its origin continent, by origin continent. h) Four example simulations of dynamics of variant spread and detection. Each point represents a country that

308 has seen at least one variant infection by the day the variant is detected, coloured by the day 309

310 of the first infection. Triangles and inverted triangles depict the country where the variant is

first detected and first emerged, respectively. Simulations are for variant R_e of 1.6. 311

312



315 Fig. 4. The time to detection under varying global distributions of global respiratory

- 316 virus genomic sequencing infrastructure. a) Comparison of time to variant detection for
- 317 different global strategies for the global distribution of genomic surveillance infrastructure.
- 318 Each value of variant R_e corresponds to a distinct scenario of variant emergence (n = 10.000
- 319 for each). Thin and thick lines correspond to 95% and 50% CIs, respectively. b) The
- 320 cumulative number of global variant infections by the day of variant detection by strategy,
- 321 analogous to a. c) Total global sequencing output relative to the 2022 baseline by strategy. d)
- 322 The probability that the variant is first detected in its origin continent, by strategy. e)
- Comparison of the mean time between the first detection of the variant globally, and the first 323
- 324 local within-country infection, by strategy, for individual countries, averaged across values of
- 325 variant R_e . Each point corresponds to a country, coloured by continent. Boxplots show the
- 326 median, first and third quartiles, and minimum and maximum values.
- 327

328

330 **Online Methods**

331

332 Sequence metadata analysis

333

334 We downloaded metadata corresponding to all SARS-CoV-2 genomes in the GISAID¹³ 335 database with collection date between January 1st 2022 and January 1st 2023 and submission 336 date up to July 1st 2023 (n = 6,894,449). For each country with at least one sequence in the 337 dataset, we computed the weekly sequencing rate by dividing the number of viruses sampled 338 in that country by 52 and the country's population size in millions, yielding a sequencing rate 339 in units of sequences per million people per week (S/M/wk). Population sizes for July 1st 340 2022 were extracted from the United Nations World Population Prospects 2022 341 (https://population.un.org/wpp/Download/Standard/MostUsed/). For each sequence, we 342 computed the turnaround time from the number of days between the sample collection and 343 submission day in GISAID. We extracted countries' per capita gross domestic product 344 (GDP) for 2022, or the most recent year before 2022 if data for 2022 was unavailable, from 345 the World Bank (https://data.worldbank.org/indicator/NY.GDP.PCAP.CD (last updated 346 2023/10/26)). We extracted income classifications for each country for fiscal year 2024 from 347 the World Bank (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-348 bank-country-and-lending-groups). For the analysis of seasonal influenza sequencing output, 349 we downloaded metadata for all seasonal influenza haemagglutinin sequences from humans with sampling date between January 1st 2018 and January 1st 2019 (n = 28,992) as the last full 350 351 year for which sequencing would have been minimally affected by the COVID-19 pandemic.

352

- 353 Surveillance simulations
- 354

355 In all analyses, we assumed that a variant virus emerges in the context of circulating wildtype 356 virus. In our simulations, both variant and wildtype epidemiological dynamics are described 357 by a susceptible-infected-recovered (SIR) compartmental model with infectious period $1/\gamma$ 358 equal to 5 days for both viruses, with no interactions between genotypes. We simulated 359 variant epidemics under a range of values of variant R_e at time of introduction (variant R_e = 360 1.2, 1.3, 1.6, and 2). In the main text, we assumed a different scenario of variant emergence 361 for each value of variant R_e , characterized by a wildtype (wt) R_e at time of variant 362 introduction and a wildtype prevalence at time of variant introduction (variant $R_e = 1.2$: wt R_e

363 = 1, wt prevalence = 0.1%; variant $R_e = 1.3$: wt $R_e = 1.05$, wt prevalence = 0.2%; variant $R_e =$ 1.6: wt $R_e = 1.1$, wt prevalence = 0.5%; variant $R_e = 2$: wt $R_e = 1$, wt prevalence = 2%). These 364 scenarios were chosen such that circulation dynamics of wildtype and variant were 365 366 comparable (e.g. the emergence of a highly transmissible variant in the background of high 367 wildtype prevalence). In the Extended Data, we show the same analyses for all combinations of variant R_e and scenario of variant emergence (e.g. a variant with $R_e = 2$ with wildtype 368 369 dynamics corresponding to the scenario for variant $R_e = 1.2$ (wt $R_e = 1$, wt prevalence = 370 0.1%)). Epidemic dynamics for each scenario in the main text are shown in Extended Data 371 Fig. 2. We note that, for any combination of initial variant proportion and variant proportion 372 logistic growth rate, including those not explicitly discussed in this study, the mathematical 373 model derived below can be used to compute the expected time to variant detection, for any 374 sequencing rate. 375 376 For the single-country analyses presented in Fig. 2, we assumed a population of 100 million and turnaround time of two weeks. We deterministically simulated variant and wildtype 377

378 epidemics, starting with one variant-infected individual, and computed the variant proportion 379 f(t) through time. For each sequencing rate and given f(t), we computed the expected day of

380 detection with 95% confidence as the day on which the probability that zero wildtype

381 sequences would have been binomially sampled up to and including that day declined below

382 0.05. On each day, the total number of samples to sequence was assumed to be a Poisson-

383 valued random variable with rate given by the sequencing rate. For each sequencing rate, the

384 day of detection was computed as the median across 100 replicates. To compute the

equivalent fold increase in sequencing rate for each reduction in turnaround time, we 385 386 computed the slope of a linear model that relates the logarithm of the sequencing rate to the

387 simulated day of detection for 1 < n < 100 S/M/wk.

388

389 Mathematical model

390

391 To derive a mathematical model for the relationship between sequencing rate and time to

392 variant detection, we based our analyses on the premise that, starting from a single

393 introduction, the proportion of all new infections of a particular virus type that is attributable

- 394 to a variant virus with a transmission advantage at time t follows a logistic growth function
- $f(t) = \frac{1}{1 + \frac{1 f_0}{f_0} e^{-st}}$. Here f_0 is the initial variant proportion relative to all circulating virus and s 395

396 is the variant proportion's logistic growth rate. Given that we are sampling to sequence n

397 samples per unit time, the binomial probability that the variant is detected at or before time

398 step τ is

399
$$P(t \le \tau) = 1 - \prod_{t=0}^{\tau} \left[1 - \frac{1}{1 + \frac{1-f_0}{f_0} e^{-st}} \right]^n [\text{Eq. 1}]$$

If we define $q = 1 - P(t \le \tau)$ (i.e. the probability that the variant will not be detected before 400 401 or during time step τ), we can rewrite Eq. 1 as:

402
$$\tau = \frac{\ln[(q^{-s/n}-1)/f_0]+1}{s} \text{ [Eq. 2]}$$

403 Hence, for given s, f_0 , and n, and q, Eq. 2. computes the day on which the variant will have 404 been detected with confidence level 1-q. We validated Eq. 2 by comparing the simulated time 405 to detection as shown in Fig. 2 to time to detection predicted using Eq. 2. Details are given in 406 the Supplementary Information.

407

Metapopulation model 408

409

410 We used a metapopulation model that couples local SIR dynamics with global migration to

411 simulate the global spread of a variant, given a single index country. Given a rate of

412 movement w_{nm} from population m to n, the expected number of variant-infected (I_n) and

413 variant-susceptible (S_n) people in population *n* with population size N_n , given transmission

rate β and recovery rate γ , is described by 414

415
$$\partial_t I_n = \frac{\beta S_n I_n}{N_n} - \gamma I_n + \sum_{m \neq n} (w_{nm} I_m - w_{mn} I_n)$$

416
$$\partial_t S_n = \frac{-\beta S_n I_n}{N_n} + \sum_{m \neq n} (w_{nm} S_m - w_{mn} S_n)$$

This model is the basis of the model used by Brockmann et al.²⁰ to fit empirical arrival times 417 418 for multiple respiratory viruses to global air transportation data. We used the estimated 419 pairwise number of trips between all countries from the Global Transnational Mobility $(\text{GTM})^{41}$ to inform w_{nm} . Specifically, for any two countries *n* and *m* we computed w_{nm} by 420 421 dividing the number of trips from country *m* to *n* in the year 2016 by the population size of 422 country *m* and by 365. Modelled arrival times using the GTM have been shown to strongly correlate with those from the global air transportation network⁴². For each value of variant R_{e} , 423 we performed 10,000 independent simulations of the metapopulation model, assuming that 424 425 the probability a variant virus would emerge in a particular country is proportional to the

426 country's relative population size (simulations initialized in Africa: n = 1793; Asia: n = 5946, Europe: n = 934; North America: n = 739; Oceania: n = 54; South America: n = 534). We 427 428 integrated the model forward in time at a daily timescale using a tau-leap algorithm, which 429 also furnishes the epidemic dynamics and global spread with stochasticity. Each simulation 430 was initialized with an infected population of 10 individuals. We validated the model by 431 comparing the simulated spread dynamics to simulations using an equivalent model in 432 GLEAMviz 7.2^{23,24} (www.gleamviz.org), a global metapopulation model that incorporates 433 dynamics of air travel and mobility. Details are given in the Supplementary Information.

434

435 Genomic surveillance simulations

436

437 We performed the genomic surveillance simulations using empirical turnaround times and 438 sampling rates for each country, using data for 2022. For each sequence in GISAID, we 439 computed the time T between the sample's collection date and submission date. In some 440 cases, sequence analysis might have been performed but the sequence would only later be 441 deposited in GISAID. Hence, given the computed turnaround time T, we assumed that a sequence's adjusted turnaround time \tilde{T} was equal to ϕT , for $0 < \phi < 1$. In the main text, $\phi = 1$, 442 and we performed sensitivity analyses for $\phi = 0.25$ and $\phi = 0.5$. For each country c, the 443 444 turnaround-time specific sequencing rate in unit of sequences per day $n_{\rm xc}$, for each value of 445 turnaround time x in days, was equal to the country's total sequencing rate in sequences per day multiplied by the proportion of sequences from that country with $\tilde{T} = x$. 446

447

For each country, for each simulation, starting from the first day on which the number of new 448 449 variant infections exceeded 10 onwards, we deterministically simulated the wildtype 450 epidemic dynamics. For each value of variant R_e , we assumed the same scenario of variant emergence (characterized by a wildtype prevalence and wildtype R_e) as in the single-country 451 analyses presented in Figure 3. In Extended Data Fig. 6, we show the same analyses for all 452 453 combinations of variant R_e and scenario of variant emergence. Until the first day on which variant incidence exceeded 10, wildtype incidence was assumed to be equal to wildtype 454 455 incidence on the first day of the simulated wildtype epidemic, to account for the stochasticity 456 observed when the number of infections was small and the potential for stochastic variant 457 extinction.

459	Using the simulated variant and wildtype incidence on each day, we computed the variant
460	proportion through time $f(t)$. For each country c , on each day t , we used the simulated
461	country-specific variant proportion $f_c(t)$ to simulate genomic surveillance by, for each value
462	of turnaround time x, generating a sample count $\tilde{n}_{x,c} \sim \text{Poisson}(n_{x,c})$, using the estimated
463	turnaround-time specific sequencing rates $n_{x,c}$ described above, and simulating the total
464	number of variant samples $V_c(t) = \sum_{x=0}^t v_{x,c}$, with $v_{x,c} \sim \text{Binomial}(\tilde{n}_{x,c}, f_c(t-x))$. In each of
465	10,000 replicate simulations, and for each strategy for the global distribution of surveillance
466	infrastructure, we computed the detection day as the first day t on which $V_c(t)$ was at least one
467	in at least one country c. We defined the detection country as the first country for which this
468	held.
469	
470	To investigate the sensitivity of our results with respect to mobility rates, we multiplied each
471	country's mobility rate by 3 and 1/3, representing faster and slower spread, respectively, and
472	re-simulated the epidemic dynamics. We applied the same genomic surveillance simulations
473	to the epidemic simulations with increased and reduce mobility rates, respectively, to assess
474	the sensitivity of our results to the mobility dynamics underlying global variant spread.
475	
476	Global surveillance strategies
477	
478	We investigated four strategies for the global distribution of sequencing infrastructure:
479	
480	Strategy 1: the 2022 baseline. For each country, turnaround time-specific sequencing rates
481	were extracted from GISAID metadata.
482	
483	Strategy 2: Equivalent to strategy 1, but individual countries' sequencing output capped at 30
484	S/M/wk. Countries that sequenced at rates exceeding 30 S/M/wk had their sequencing output
485	capped by dividing sequencing rate uniformly across all values of turnaround time such that
486	total output across all values of turnaround time was equal to 30 S/M/wk.
487	
488	Strategy 3: the 2022 baseline + a global minimum sequencing capacity of 2 S/M/wk at 14 day
489	turnaround time in each country. If a country already satisfied this requirement (i.e., the sum
490	of turnaround time-specific sequencing rates with turnaround time ≤ 14 days was equal to or
491	greater than 2 S/M/wk), its sequencing rates were unchanged relative to strategy 1. If a

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23297901; this version posted November 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

492 country satisfied the sequencing rate across all values of turnaround time, but not within the 493 required two-week turnaround time, the deficit in S/M/wk in the sum of turnaround time-494 specific sequencing rates with turnaround time ≤ 14 days was uniformly removed from the 495 sequencing rates exceeding 14 days and added to the sequencing rate corresponding to a 496 turnaround time of 14 days. Hence, in this scenario, total sequencing output remained 497 unchanged, and the minimum sequencing capacity was attained by reducing turnaround time. 498 If a country did not satisfy the minimum sequencing rate at all, all sequencing output 499 corresponding to a sequencing rate >14 days was set to a turnaround time of 14 days. The 500 remaining deficit in S/M/wk in the sum of turnaround time-specific sequencing rates with 501 turnaround time ≤ 14 days was added to the sequencing rate corresponding to a turnaround 502 time of 14 days. 503

504 Strategy 4: In countries that, after capping according to strategy 2, did not satisfy the

505 minimum sequencing rate of 2 S/M/wk at 14 day turnaround time, this minimum was ensured

506 analogous to Strategy 3.

508 509	Refer	ences
510	1.	Ladner, J. T. & Sahl, J. W. Towards a post-pandemic future for global pathogen
511		genome sequencing. PLOS Biol. 21, e3002225 (2023).
512	2.	Hill, V. et al. Toward a global virus genomic surveillance network. Cell Host Microbe
513		31 , 861–873 (2023).
514	3.	Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in
515		southern Africa. Nature 603, 679–686 (2022).
516	4.	Cherian, S. et al. SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R,
517		in the Second Wave of COVID-19 in Maharashtra, India. Microorganisms vol. 9 at
518		https://doi.org/10.3390/microorganisms9071542 (2021).
519	5.	Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage
520		B.1.1.7 in England. Science (80). 372, eabg3055 (2021).
521	6.	Chen, Z. et al. Global landscape of SARS-CoV-2 genomic surveillance and data
522		sharing. Nat. Genet. 54, 499-507 (2022).
523	7.	Tegally, H. et al. The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly
524		expanding genomic surveillance. Science (80). 378, eabq5358 (2023).
525	8.	Brito, A. F. et al. Global disparities in SARS-CoV-2 genomic surveillance. Nat.
526		Commun. 13, 7003 (2022).
527	9.	Knyazev, S. et al. Unlocking capacities of genomics for the COVID-19 response and
528		future pandemics. Nat. Methods 19, 374-380 (2022).
529	10.	Hill, V., Ruis, C., Bajaj, S., Pybus, O. G. & Kraemer, M. U. G. Progress and
530		challenges in virus genomic epidemiology. Trends Parasitol. 37, 1038–1049 (2021).
531	11.	Lin, C. et al. Towards equitable access to public health pathogen genomics in the
532		Western Pacific. Lancet Reg. Heal West. Pacific 18, (2022).
533	12.	Wohl, S., Lee, E. C., DiPrete, B. L. & Lessler, J. Sample size calculations for pathogen
534		variant surveillance in the presence of biological and systematic biases. Cell Reports
535		<i>Med.</i> 4 , (2023).
536	13.	Méder, Z. Z. & Somogyi, R. Optimal capacity sharing for global genomic surveillance.
537		<i>Epidemics</i> 43 , 100690 (2023).
538	14.	Boyle, L. et al. Selective sweeps in SARS-CoV-2 variant competition. Proc. Natl.
539		Acad. Sci. 119, e2213879119 (2022).
540	15.	Wilkinson, E. et al. A year of genomic surveillance reveals how the SARS-CoV-2
541		pandemic unfolded in Africa. Science (80). 374, 423-431 (2021).

542	16.	Jones, K. E. et al. Global trends in emerging infectious diseases. Nature 451, 990-993
543		(2008).
544	17.	Fraser, C. et al. Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings.
545		Science (80). 324 , 1557–1561 (2009).
546	18.	Davis, J. T. et al. Cryptic transmission of SARS-CoV-2 and the first COVID-19 wave.
547		<i>Nature</i> 600 , 127–132 (2021).
548	19.	Hodcroft, E. B. et al. Spread of a SARS-CoV-2 variant through Europe in the summer
549		of 2020. Nature 595 , 707–712 (2021).
550	20.	Brockmann, D. & Helbing, D. The Hidden Geometry of Complex, Network-Driven
551		Contagion Phenomena. Science (80). 342, 1337-1342 (2013).
552	21.	Tegally, H. et al. Dispersal patterns and influence of air travel during the global
553		expansion of SARS-CoV-2 variants of concern. Cell 186, 3277-3290.e16 (2023).
554	22.	Bedford, T., Cobey, S., Beerli, P. & Pascual, M. Global Migration Dynamics Underlie
555		Evolution and Persistence of Human Influenza A (H3N2). PLOS Pathog. 6, e1000918-
556		(2010).
557	23.	Balcan, D. et al. Seasonal transmission potential and activity peaks of the new
558		influenza A(H1N1): a Monte Carlo likelihood analysis based on human mobility. BMC
559		Med. 7, 45 (2009).
560	24.	Van den Broeck, W. et al. The GLEaMviz computational tool, a publicly available
561		software to explore realistic epidemic spreading scenarios at the global scale. BMC
562		Infect. Dis. 11, 37 (2011).
563	25.	Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data - from
564		vision to reality. Euro surveillance : bulletin Europeen sur les maladies transmissibles
565		= European communicable disease bulletin vol. 22 at https://doi.org/10.2807/1560-
566		7917.ES.2017.22.13.30494 (2017).
567	26.	Kalia, K., Saberwal, G. & Sharma, G. The lag in SARS-CoV-2 genome submissions to
568		GISAID. Nat. Biotechnol. 39, 1058–1060 (2021).
569	27.	Sahadeo, N. S. D. et al. Implementation of genomic surveillance of SARS-CoV-2 in
570		the Caribbean: Lessons learned for sustainability in resource-limited settings. PLOS
571		<i>Glob. Public Heal.</i> 3 , e0001455 (2023).
572	28.	World Health Organization (WHO). Updated working definitions and primary actions
573		for SARS-CoV-2 variants, 4 October 2023. (2023).
574	29.	Oude Munnink, B. B. et al. The next phase of SARS-CoV-2 surveillance: real-time
575		molecular epidemiology. Nat. Med. 27, 1518–1524 (2021).

- 576 30. Genomic sequencing in pandemics. Lancet 397, 445 (2021).
- 577 31. Tao, K. et al. The biological and clinical significance of emerging SARS-CoV-2
- 578 variants. Nat. Rev. Genet. 22, 757-773 (2021).
- 579 32. Madhi, S. A. et al. Population Immunity and Covid-19 Severity with Omicron Variant 580 in South Africa. N. Engl. J. Med. 386, 1314-1326 (2022).
- 581 Hill, V. et al. The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in 33.
- 582 the UK. Virus Evol. 8, veac080 (2022).
- 34. Pandemics move faster than funders. Lancet 402, 367 (2023). 583
- 584 35. Han, A. X. et al. SARS-CoV-2 diagnostic testing rates determine the sensitivity of 585 genomic surveillance programs. Nat. Genet. 55, 26-33 (2023).
- 36. 586 Salyer, S. J. et al. The first and second waves of the COVID-19 pandemic in Africa: a 587 cross-sectional study. Lancet 397, 1265–1275 (2021).
- 588 37. Ellingford, J. M. et al. Genomic and healthcare dynamics of nosocomial SARS-CoV-2 589 transmission. *Elife* 10, e65453 (2021).
- 590 38. Duchene, S. et al. Temporal signal and the phylodynamic threshold of SARS-CoV-2. 591 Virus Evol. 6, veaa061 (2020).
- 592 39. Gardy, J. L. & Loman, N. J. Towards a genomics-informed, real-time, global pathogen 593 surveillance system. Nat. Rev. Genet. 19, 9-20 (2018).
- 594 40. Inzaule, S. C., Tessema, S. K., Kebede, Y., Ogwell Ouma, A. E. & Nkengasong, J. N.
- 595 Genomic-informed pathogen surveillance in Africa: opportunities and challenges. 596 Lancet Infect. Dis. 21, e281–e289 (2021).
- 597 41. Deutschmann, E., Recchi, E. & Vespe, M. Assessing Transnational Human Mobility 598 on a Global Scale BT - Migration Research in a Digitized World: Using Innovative
- 599 Technology to Tackle Methodological Challenges. in (eds. Pötzschke, S. & Rinken, S.)
- 600 169–192 (Springer International Publishing, 2022). doi:10.1007/978-3-031-01319-5 9.
- 601 42. Klamser, P. P. et al. Inferring country-specific import risk of diseases from the world
- 602 air transportation network. arXiv e-prints arXiv:2304.12087 at
- 603 https://doi.org/10.48550/arXiv.2304.12087 (2023).
- 604

605 **Data availability**

- 606
- 607 Data on global population sizes are available from the United Nations World Population
- Prospects 2022 (https://population.un.org/wpp/Download/Standard/MostUsed/). Data on 608
- 609 country GDP (https://data.worldbank.org/indicator/NY.GDP.PCAP.CD) and income

610	classification (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-
611	bank-country-and-lending-groups) is available from the World Bank. The Global
612	Transnational Mobility Dataset is available from the Global Mobilities Project
613	(https://migrationpolicycentre.eu/globalmobilities/dataset/). Metadata on global SARS-CoV-2
614	and seasonal influenza virus sequencing rates were extracted from GISAID
615	(www.gisaid.org).
616	
617	Code availability
618	
619	Custom code and data used to generate the results in this study is publicly available at
620	https://github.com/AMC-LAEB/genomic_surveillance_equity. Raw global epidemic
621	simulation output is available at https://zenodo.org/records/10051237.
622	
623	Acknowledgements
624	
625	This work was supported by the European Research Council (grant number 818353). We
626	gratefully acknowledge the originating and submitting laboratories that generated the
627	sequence data in GISAID that this study relies on.
628	
629	Author contributions
630	
631	S.P.d.J., B.E.N., A.X.H., and C.A.R. designed the research; S.P.d.J. and A.X.H. performed
632	the data analysis and modelling work; S.P.d.J., A.X.H., and C.A.R. wrote the first draft of the
633	paper. All authors contributed to the critical revision of the paper.
634	
635	Competing interests
636	
637 638 639	The authors declare no competing interests related to this work.



Extended Data Fig. 1. Relationship between median turnaround time and per capita

- **GDP.** Each point corresponds to a country (n = 188), coloured by continent.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23297901; this version posted November 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



647 648

649 Extended Data Fig. 2. Different scenarios of variant emergence. For each of the values of

650 variant R_e , the corresponding panel shows the epidemiological dynamics of variant and

651 wildtype for that scenario of variant emergence, starting from the day of variant introduction.

For each value of variant R_e , the scenario of variant emergence is characterised by a different

653 value of wildtype R_e and wildtype prevalence at introduction.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23297901; this version posted November 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

655



656 657 Extended Data Fig. 3. The dependence of time to variant detection on sequencing rate

658 for varying scenario of variant emergence. a) Relationship between sequencing rate and

659 the number of days until the variant will have been detected with 95% confidence. The small 660 black tick marks on the x-axes in this plot and in **b** show country-specific SARS-CoV-2

661 sequencing rates for 2022. Each panel corresponds to a different scenario of variant

662 emergence, characterized by a wildtype (wt) R_e and wildtype prevalence at introduction. In

each panel, lines are colored by value of variant R_e . **b)** Relationship between sequencing rate 663

and the reduction in time to variant detection that results from increasing the existing 664

sequencing rate (x-axis) by 1 S/M/wk. 665





669 variant detection on sequencing rate for varying scenario of variant emergence. a) 670

671 Relationship between sequencing rate and the number of variant infections by the day the

672 variant will have been detected with 95% confidence. The small black tick marks on the x-

axes in this plot and in **b** show country-specific SARS-CoV-2 sequencing rates for 2022. 673

674 Each panel corresponds to a different scenario of variant emergence, characterized by a

675 wildtype (wt) R_e and wildtype prevalence at introduction. In each panel, lines are colored by

value of variant R_e . b) Relationship between sequencing rate and the reduction in the number 676

- 677 of variant infections by the day of detection that results from increasing the existing
- sequencing rate (x-axis) by 1 S/M/wk. 678
- 679 680

681



682 683

Extended Data Fig. 5. Validation of the metapopulation model against GLEAM. For ten

684 geographically representative countries, global variant spread was simulated, initialised in the country's capital city, in GLEAM. For each of the ten index countries, all global countries' 685

686 epidemic onset timings as simulated using GLEAM were compared against the countries'

epidemic onset timings as simulated using the epidemic model used in this study. For both 687

models, timings were computed as the median across 10 independent simulations. 688

689 Simulations are for a variant R_e of 1.6.







693 Extended Data Fig. 6. Time to global variant detection by strategy and scenario of

694 variant emergence. a) Time to global variant detection by strategy for the global distribution 695 of respiratory virus surveillance infrastructure, by variant R_e , for varying scenario of variant 696 emergence (characterised by wildtype (wt) R_e and wildtype prevalence). Thin and thick lines 697 correspond to 95% and 50% CIs, respectively. b) Number of global variant infections by the day of first detection by strategy for the global distribution of respiratory virus surveillance 698 699 infrastructure, by variant R_e , for varying scenario of variant emergence (characterised by 700 wildtype (wt) R_e and wildtype prevalence). Thin and thick lines correspond to 95% and 50% CIs, respectively. 701

702

704



705

706

707 Extended Data Fig. 7. Sensitivity analysis for delay in time to GISAID submission. Time

708 to global variant detection by strategy for the global distribution of respiratory virus

709 surveillance infrastructure, by variant R_e , for varying scenario of variant emergence

(characterised by wildtype (wt) R_e and wildtype prevalence). Thin and thick lines correspond 710

to 95% and 50% CIs, respectively. Given a sequence in GISAID's computed turnaround time 711

712 T, a sequence's adjusted turnaround time \tilde{T} was equal to ϕT . These adjusted turnaround times

713 were used to inform country-specific sequencing infrastructure in the global genomic

714 surveillance simulations.

715



718

Extended Data Fig. 8. Sensitivity analysis for mobility rate. Time to global variant 719

720 detection by strategy for the global distribution of respiratory virus surveillance

infrastructure, by variant R_e , for varying scenario of variant emergence (characterised by 721

722 wildtype (wt) R_e and wildtype prevalence). Thin and thick lines correspond to 95% and 50%

723 CIs, respectively. Each row corresponds to a modified global mobility rate (top: baseline

724 mobility rate multiplied by 3; bottom: baseline mobility rate divided by 3). medRxiv preprint doi: https://doi.org/10.1101/2023.11.01.23297901; this version posted November 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



725

726 Extended Data Fig. 9. The global distribution of seasonal influenza sequencing output in

727 **2018.** The cumulative proportion of the global population that accounts for a cumulative

728 proportion of global sequence output. Solid grey lines show the smallest proportion of the

population that accounts for 50% of sequencing output. Dashed grey lines show the smallest

proportion of sequencing output that is accounted for by 50% of the global population. Data

is for seasonal influenza sequences in GISAID collected from humans in 2018.

732



735 Extended Data Fig. 10. The relationship between sequencing rate and error in estimated

734

736 variant proportion. For each sequencing rate given on the x-axis, for varying true variant

proportion and population size, the *v*-axis shows the maximum error in the estimated weekly 737

738 proportion of total infections attributable to the variant. This maximum error is presented for

739 varying confidence (i.e. the y-axis represents the error that the error in the estimated variant

proportion relative to the true variant proportion will be smaller than n% of the time, for n740 741 given by the confidence level).